Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential (NASDAQ:GLUE)
· seekingalpha.com
Monte Rosa Therapeutics, Inc. is Buy-rated: molecular glue degrader biotech with Novartis/Roche partnerships and strong Phase 1 data. Click for more on GLUE.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...